Literature DB >> 2792116

The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction.

P Brugada1, M Talajic, J Smeets, R Mulleneers, H J Wellens.   

Abstract

Multivariate analysis using 70 variables in 200 patients who suffered from ventricular tachycardia or ventricular fibrillation after myocardial infarction detected eleven variables that were associated with an increased risk of sudden arrhythmic death and cardiac death during a mean follow-up period of 2 years. Four of the 11 variables came from the patient's clinical history: (1) cardiac arrest at the time of the first spontaneous episode of arrhythmia, (2) New York Heart Association functional class for dyspnoea = III, (3) ventricular tachycardia or ventricular fibrillation occurring early (after 3 days and within 2 months) after myocardial infarction, (4) multiple myocardial infarctions before the first episode of ventricular tachyarrhythmia. Total mortality, incidence of sudden arrhythmic death and of non-sudden cardiac death increased with an increasing number (zero, one, two, three, four) of variables seen in individual patients. Patients with zero or one variable had an incidence of sudden death of 2.8% and a 4.2% incidence of non-sudden cardiac death at 26 months, while patients with more than two variables had a 13.5% and a 20.3% incidence respectively of sudden and non-sudden cardiac death. The strongest predictor of sudden death was the occurrence of cardiac arrest during the first spontaneous episode of ventricular arrhythmia. The strongest predictor of non-sudden cardiac death was the New York Heart Association functional class. The use of the four variables to stratify risk revealed seven subgroups of patients with incidences of sudden death ranging from 0 to 28%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2792116     DOI: 10.1093/oxfordjournals.eurheartj.a059559

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

Review 1.  Are drugs and catheter ablation effective for treating ventricular arrhythmias in populations that cannot afford implantable cardioverter defibrillators?

Authors:  K K Talwar; N Naik; R Juneja
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 2.  Diagnosis and management of ventricular tachycardia.

Authors:  M Dancy
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

3.  Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.

Authors:  L M Rodríguez; E B Sternick; J L Smeets; C Timmermans; K den Dulk; G Oreto; H J Wellens
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

4.  Surgery for postinfarction ventricular tachycardia in the pre-implantable cardioverter defibrillator era: early and long term outcomes in 100 consecutive patients.

Authors:  J P Bourke; R W Campbell; J M McComb; S S Furniss; J C Doig; C J Hilton
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

5.  Managing ventricular tachyarrhythmias in the developing world: insights from recent ICD trials.

Authors:  K K Talwar; N Naik
Journal:  Indian Pacing Electrophysiol J       Date:  2001-10-01

6.  Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest.

Authors:  D Böcker; M Block; F Isbruch; C Fastenrath; M Castrucci; D Hammel; H H Scheld; M Borggrefe; G Breithardt
Journal:  Br Heart J       Date:  1995-02

7.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

8.  Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.

Authors:  A Proclemer; D Facchin; D Vanuzzo; G A Feruglio
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

9.  Strategies for the prevention and treatment of sudden cardiac death.

Authors:  Emad F Aziz; Fahad Javed; Balaji Pratap; Eyal Herzog
Journal:  Open Access Emerg Med       Date:  2010-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.